Dabur India Q4 Review - Strong Growth On Favourable Base: Dolat Capital
BQ Blue’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BloombergQuint’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.
Dolat Capital Report
Dabur India Ltd.’s Q4 FY21 results were below our estimate.
Domestic fast moving consumer goods business registered strong volume growth of 25.4% YoY on the back of favorable base.
Growth in the domestic market was driven by healthcare (up 22.9%), home and personal care (up 32.6%) businesses and revival in food and beverages (up 27.6%).
Overall, the company witnessed 5-6% raw material inflation. It took price hike of 3% and is contemplating further increases to mitigate the same.
Healthcare contribution declined from 35.4% in Q4 FY20 to 33.9% in Q4 FY21.
However, with resurgence of Covid-19 cases and slew of new launches, the healthcare category is poised to grow faster.
Click on the attachment to read the full report:
This report is authored by an external party. BloombergQuint does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BloombergQuint.
Users have no license to copy, modify, or distribute the content without permission of the Original Owner.